- Radiation oncology. // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS82
Presents an abstract of the research manuscript `Evaluation of an immobilization technique for intrathoracic radiotherapy,' by R. Halperin.
- Rapid Decline of Follicular Lymphoma-Associated Chylothorax after Low Dose Radiotherapy to Retroperitoneal Lymphoma Localization. Van De Voorde, Lien; Vanneste, Ben; Borger, Jacques; Troost, Esther G. C.; Werner, Philo // Case Reports in Hematology;2014, p1
Chylothorax is caused by disruption or obstruction of the thoracic duct or its tributaries that results in the leakage of chyle into the pleural space. A number of interventions have been used to treat chylothorax including the treatment of the underlying disease. Lymphoma is found in 70% of...
- Answer to the Letter to the Editor of T. B. Grivas concerning 'A comprehensive review of thoracic deformity parameters in scoliosis' by Harris JA, et al. Eur Spine J (2014): DOI 10.1007/s00586-014-3580-8. Harris, Jonathan // European Spine Journal;Mar2015, Vol. 24 Issue 3, p619
A response from the author of the article "A comprehensive review of thoracic deformity parameters in scoliosis," by J. A. Harris and colleagues.
- Thoracic Radiotherapy Does Not Prolong Survival in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer. Johnson, David H.; Einhorn, Lawrence H.; Bartolucci, Alfred; Birch, Robert; Omura, George; Perez, Carlos A.; Greco, F. Anthony // Annals of Internal Medicine;7/1/90, Vol. 113 Issue 1, p33
Compares the survival of patients with locally advanced non-small cell lung cancer treated with single-agent vindesine, thoracic radiotherapy, or both treatment modalities. Characteristics of the patients; Response to induction therapy; Adequacy of radiotherapy.
- A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group. Segawa, Y; Ueoka, H; Kiura, K; Kamei, H; Tabata, M; Sakae, K; Hiraki, Y; Kawahara, S; Eguchi, K; Hiraki, S; Harada for the Okayama Lung Cancer Study Group, Mine // British Journal of Cancer;1/1/2000, Vol. 82 Issue 1, p104
A recent meta-analysis and randomized studies have demonstrated that combined chemoradiotherapy is associated with a survival advantage for selected patients with locally advanced unresectable non-small-cell lung cancer (NSCLC). We conducted a phase II study of combined chemoradiotherapy to find...
- Intra-thoracic Failure Pattern and Survival Status Following 3D Conformal Radiotherapy for... Chun-Ru Chien; Shang-Wen Chen; Chang-Yao Hsieh; Ji-An Liang; Shin-Neng Yang; Chao-Yuan Huang; Fang-Jen Lin // Japanese Journal of Clinical Oncology;Feb2001, Vol. 31 Issue 2, p55
Studies the intra-thoracic failure pattern, clinical target volume (CTV) and survival status following three-dimensional conformal radiotherapy (3DCRT) boost for non-small cell lung cancer (NSCLC). Materials and methods; Intra-thoracic failures in follow-up chest CT examinations; Complications.
- Lung cancer Â· 5: State of the art radiotherapy for lung cancer. Price, A. // Thorax;May2003, Vol. 58 Issue 5, p447
Discusses the role of radiotherapy in curative and palliative treatments of patients with lung cancer. Impact of technical advances in radiotherapy physics; Emphasis on the integration of chemotherapy with radiotherapy.
- Accelerated vs. conventional radiotherapy for lung cancer. Walling, Anne D. // American Family Physician;2/15/1998, Vol. 57 Issue 4, p829
Presents a study by M. Saunders on the accelerated radiotherapy used for lung cancer against conventional radiotherapy, orignially from the journal `Lancet,' volume 350, 1997 issue. Details on the study; Examination of the study; Findings of the study.
- Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma. Koukourakis, M I; Bahlitzanakis, N; Froudarakis, M; Giatromanolaki, A; Georgoulias, V; Koumiotaki, S; Christodoulou, M; Kyrias, G; Skarlatos, J; Kostantelos, J; Beroukas, K // British Journal of Cancer;8/1/99, Vol. 80 Issue 11, p1792
Docetaxel has shown remarkable radiosensitizing in vitro properties. In a previous phase I/II dose escalation study in non-small-cell lung cancer (NSCLC) we observed a high response rate after concomitant boost radiotherapy and weekly docetaxel. The maximum tolerated dose was 30 mg m[SUP-2]...